ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and
the Prevention of Sudden Cardiac Death: A Report of the American College of …

Among patients with HF or evidence of LV dysfunction after acute MI enrolled in the Optimal
Trial in Myocardial Infarction With the Angiotensin II Antagonist Losartan (OPTIMAAL) …

Background—Accurate risk stratification is crucial for effective treatment planning after
myocardial infarction (MI). Previous studies suggest that the peri-infarct border zone may be …

considered unusual cells that are created only during embryonic and fetal development so
that their total number in the heart is established at birth and no further growth occurs …

838 medication have significant differences with regard to their ancillary pharmacological
properties and thereby also their profile at a molecular/cellular level. Furthermore, these …

ContextSudden cardiac death (SCD) is a major challenge facing contemporary cardiology.
For an increasing number of patients, the current standard of care for the treatment and …

Objectives: We conducted a collaborative cohort study to evaluate the predictive power of
microvolt T-wave alternans (TWA) in patients with preserved left ventricular ejection fraction …

Sympathetic hyperinnervation occurs in human ventricular tissue after myocardial infarction
and may contribute to arrhythmias. Aberrant sympathetic sprouting is associated with …

The aim of this study was to review published data on gender differences in cardiac
electrophysiology and in the presentation and clinical treatment of arrhythmias. The …

Aims: Because of the prognostic importance of LV dysfunction following an AMI and the
increasing use of electrical and/or mechanical interventions in patients with LV systolic …